HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital
September 12 2022 - 8:30AM
Heart Test Laboratories, Inc d.b.a HeartSciences (NASDAQ: HSCS), a
medical technology company focused on applying innovative AI-based
technology to an ECG (also known as an EKG) to significantly expand
and improve an ECG’s clinical usefulness by detecting cardiac
dysfunction, today announced that management has been invited to
participate and showcase the company’s technology at the
Inauguration Ceremony of the Center for Innovation at the Rutgers
Robert Wood Johnson University Hospital on September 14, 2022, in
New Brunswick, New Jersey.
With a rapid technology transformation occurring in cardiology,
the Rutgers Robert Wood Johnson University Hospital is investing in
the vision of a technology-enabled cardiovascular service that will
enhance all aspects of the patient journey by leveraging advanced
technologies such as innovative devices, robotics and artificial
intelligence (AI) capabilities. The Center is designed to encourage
a multidisciplinary approach where clinicians work with industry to
investigate and apply new technologies, to solve medical
problems.
“We are honored to accept this invitation as we share their
mission of transforming cardiology technologies to enhance patient
outcomes. We are currently working with the Rutgers Health network,
which includes the Robert Wood Johnson University Hospital, as part
of our FDA pivotal validation study and applaud their commitment to
the latest technologies. We are excited to participate in the
celebration of this Innovation Center and showcase the MyoVista, as
we continue to strengthen our relationship with Rutgers,” stated
Mr. Andrew Simpson, CEO of HeartSciences.
Robert Wood Johnson University Hospital is one of the
institutions participating in HeartSciences’ pivotal study related
to FDA submission. They are performing core lab services
related to echocardiogram overreads for all sites.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is medical
technology company focused on applying innovative AI-based
technology to an ECG (also known as an EKG) to expand and improve
an ECG’s clinical usefulness. The Company’s objective is to make an
ECG a far more valuable cardiac screening tool, particularly in
frontline or point-of-care clinical settings. HeartSciences’ first
product candidate for FDA clearance, the MyoVista® wavECG™, or the
MyoVista, is a resting 12-lead ECG that is also designed to provide
diagnostic information related to a form of cardiac dysfunction
called left ventricular diastolic dysfunction (LVDD), which has
traditionally only been available through the use of cardiac
imaging. LVDD is associated with almost all forms and
co-morbidities of heart disease including hypertension, diabetes,
valvular disease, ischemia, and reduced systolic function among
others.
The MyoVista Device additionally provides all the information
and capabilities of a full-featured conventional resting 12-lead
ECG within the same test and follows the same clinical AHA/IEC lead
placement protocol.
For more information, please visit: https://www.
heartsciences.com.
For investor and media inquiries, please
contact:
Investor Relations:
Crescendo Communications, LLC
Phone: (212) 671-1021
Email: HSCS@crescendo-ir.com
Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements are made under the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995 and are relating
to the Company's future financial and operating performance. All
statements, other than statements of historical facts, included
herein are "forward-looking statements" including, among other
things, statements about HeartSciences’ beliefs and expectations.
These statements are based on current expectations, assumptions and
uncertainties involving judgments about, among other things, future
economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict
accurately and many of which are beyond the Company's control. The
expectations reflected in these forward-looking statements involve
significant assumptions, risks and uncertainties, and these
expectations may prove to be incorrect. Investors should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Potential risks and
uncertainties include, but are not limited to, risks discussed in
HeartSciences’ filings with the U.S. Securities and Exchange
Commission at www.sec.gov. Other than as required under the
securities laws, the Company does not assume a duty to update these
forward-looking statements.
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Sep 2023 to Sep 2024